{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:06:18Z","timestamp":1765807578980,"version":"3.41.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11934-018-0821-0","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T04:52:56Z","timestamp":1530593576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Is Tamsulosin Linked to Dementia in the Elderly?"],"prefix":"10.1007","volume":"19","author":[{"given":"Jason K.","family":"Frankel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Albertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"issue":"Suppl 1","key":"821_CR1","first-page":"5","volume":"76","author":"JD McConnell","year":"1995","unstructured":"McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5\u201310.","journal-title":"Br J Urol"},{"issue":"10","key":"821_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198709033171004","volume":"317","author":"CA Peters","year":"1987","unstructured":"Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599\u2013604.","journal-title":"N Engl J Med"},{"issue":"5","key":"821_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/pros.2990050510","volume":"5","author":"JT Isaacs","year":"1984","unstructured":"Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545\u201357.","journal-title":"Prostate"},{"issue":"10","key":"821_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1210\/mend-3-10-1515","volume":"3","author":"N Kyprianou","year":"1989","unstructured":"Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol. 1989;3(10):1515\u201322.","journal-title":"Mol Endocrinol"},{"issue":"5","key":"821_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0022-5347(17)37546-8","volume":"147","author":"E Shapiro","year":"1992","unstructured":"Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147(5):1293\u20137.","journal-title":"J Urol"},{"issue":"3","key":"821_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.ju.0000097026.43866.cc","volume":"171","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171(3):1029\u201335.","journal-title":"J Urol"},{"issue":"3","key":"821_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0022-5347(17)36170-0","volume":"149","author":"H Lepor","year":"1993","unstructured":"Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149(3):640\u20132.","journal-title":"J Urol"},{"issue":"4","key":"821_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/pros.2990220404","volume":"22","author":"H Lepor","year":"1993","unstructured":"Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate. 1993;22(4):301\u20137.","journal-title":"Prostate"},{"issue":"1","key":"821_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF00586704","volume":"330","author":"K Honda","year":"1985","unstructured":"Honda K, Miyata-Osawa A, Takenaka T. Alpha 1-adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedeberg's Arch Pharmacol. 1985;330(1):16\u201321.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"6 Suppl","key":"821_CR10","first-page":"21","volume":"32","author":"H Lepor","year":"1988","unstructured":"Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988;32(6 Suppl):21\u20136.","journal-title":"Urology"},{"issue":"Suppl 2","key":"821_CR11","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88\u2013119.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"821_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1464-410X.1978.tb06210.x","volume":"50","author":"M Caine","year":"1978","unstructured":"Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50(7):551\u20134.","journal-title":"Br J Urol"},{"issue":"5","key":"821_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0024-3205(77)90066-2","volume":"21","author":"S Berthelsen","year":"1977","unstructured":"Berthelsen S, Pettinger WA. A functional basis for classification of alpha-adrenergic receptors. Life Sci. 1977;21(5):595\u2013606.","journal-title":"Life Sci"},{"issue":"2","key":"821_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0022-5347(17)51106-4","volume":"130","author":"H Hedlund","year":"1983","unstructured":"Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983;130(2):275\u20138.","journal-title":"J Urol"},{"issue":"3","key":"821_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<202::AID-PROS9>3.0.CO;2-N","volume":"30","author":"KE Andersson","year":"1997","unstructured":"Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997;30(3):202\u201315.","journal-title":"Prostate"},{"issue":"2 Pt 1","key":"821_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0022-5347(17)35544-1","volume":"150","author":"DT Price","year":"1993","unstructured":"Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150(2 Pt 1):546\u201351.","journal-title":"J Urol"},{"issue":"3","key":"821_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0022-5347(17)35083-8","volume":"151","author":"S Kobayashi","year":"1994","unstructured":"Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151(3):763\u20136.","journal-title":"J Urol"},{"issue":"3","key":"821_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0022-5347(01)65136-X","volume":"157","author":"PD Walden","year":"1997","unstructured":"Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL. Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol. 1997;157(3):1032\u20138.","journal-title":"J Urol"},{"issue":"2","key":"821_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/10799893.2010.550008","volume":"31","author":"DM Perez","year":"2011","unstructured":"Perez DM, Doze VA. Cardiac and neuroprotection regulated by alpha(1)-adrenergic receptor subtypes. J Recept Signal Transduct Res. 2011;31(2):98\u2013110.","journal-title":"J Recept Signal Transduct Res"},{"issue":"14","key":"821_CR20","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.1073\/pnas.132552699","volume":"99","author":"DG Rokosh","year":"2002","unstructured":"Rokosh DG, Simpson PC. Knockout of the alpha 1A\/C-adrenergic receptor subtype: the alpha 1A\/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci U S A. 2002;99(14):9474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"821_CR21","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1073\/pnas.94.21.11589","volume":"94","author":"A Cavalli","year":"1997","unstructured":"Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci U S A. 1997;94(21):11589\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"821_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1172\/JCI200214001","volume":"109","author":"A Tanoue","year":"2002","unstructured":"Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002;109(6):765\u201375.","journal-title":"J Clin Invest"},{"issue":"3","key":"821_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.neuroscience.2005.09.031","volume":"137","author":"MD Lapiz","year":"2006","unstructured":"Lapiz MD, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience. 2006;137(3):1039\u201349.","journal-title":"Neuroscience"},{"issue":"34","key":"821_CR24","doi-asserted-by":"publisher","first-page":"13804","DOI":"10.1073\/pnas.0702753104","volume":"104","author":"KS Rommelfanger","year":"2007","unstructured":"Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A. 2007;104(34):13804\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"821_CR25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0006-3223(99)00234-6","volume":"46","author":"EA Stone","year":"1999","unstructured":"Stone EA, Quartermain D. Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol Psychiatry. 1999;46(9):1287\u2013300.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"821_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0163-7258(99)00017-0","volume":"83","author":"J Sirvio","year":"1999","unstructured":"Sirvio J, MacDonald E. Central alpha1-adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol Ther. 1999;83(1):49\u201365.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"821_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1124\/mol.111.073734","volume":"80","author":"VA Doze","year":"2011","unstructured":"Doze VA, Papay RS, Goldenstein BL, Gupta MK, Collette KM, Nelson BW, et al. Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol. 2011;80(4):747\u201358.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"821_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0924-977X(00)00100-0","volume":"10","author":"J Knauber","year":"2000","unstructured":"Knauber J, Muller WE. Decreased exploratory activity and impaired passive avoidance behaviour in mice deficient for the alpha(1b)-adrenoceptor. Eur Neuropsychopharmacol. 2000;10(6):423\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"821_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1006\/nlme.2000.3965","volume":"75","author":"M Spreng","year":"2001","unstructured":"Spreng M, Cotecchia S, Schenk F. A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol Learn Mem. 2001;75(2):214\u201329.","journal-title":"Neurobiol Learn Mem"},{"issue":"7","key":"821_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.mp.4001351","volume":"8","author":"A Sadalge","year":"2003","unstructured":"Sadalge A, Coughlin L, Fu H, Wang B, Valladares O, Valentino R, et al. Alpha 1d adrenoceptor signaling is required for stimulus induced locomotor activity. Mol Psychiatry. 2003;8(7):664\u201372.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"821_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1734-1140(13)71509-3","volume":"65","author":"I Nalepa","year":"2013","unstructured":"Nalepa I, Kreiner G, Bielawski A, Rafa-Zablocka K, Roman A. Alpha1-adrenergic receptor subtypes in the central nervous system: insights from genetically engineered mouse models. Pharmacol Rep. 2013;65(6):1489\u201397.","journal-title":"Pharmacol Rep"},{"issue":"5","key":"821_CR32","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","volume":"185","author":"KT McVary","year":"2011","unstructured":"McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793\u2013803.","journal-title":"J Urol"},{"issue":"3","key":"821_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ucl.2016.04.009","volume":"43","author":"H Lepor","year":"2016","unstructured":"Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 2016;43(3):311\u201323.","journal-title":"Urol Clin North Am"},{"key":"821_CR34","unstructured":"Food and Drug Administration. Pediatric focused safety review: Flomax\u00ae(tamsulosin hydrochloride). Center for Drug Evaluation and Research; 2012 [Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM289947.pdf ."},{"issue":"1","key":"821_CR35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(24)36764-3","volume":"282","author":"DJ Martin","year":"1997","unstructured":"Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997;282(1):228\u201335.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"821_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1464-410X.2003.04590.x","volume":"92","author":"KE Andersson","year":"2003","unstructured":"Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int. 2003;92(9):876\u20137.","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"821_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1464-410X.2006.06104.x","volume":"97","author":"F Giuliano","year":"2006","unstructured":"Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97(Suppl 2):34\u20138. discussion 44-5","journal-title":"BJU Int"},{"issue":"4","key":"821_CR38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.18433\/J3JK5P","volume":"16","author":"K Nikolic","year":"2013","unstructured":"Nikolic K, Filipic S, Smolinski A, Kaliszan R, Agbaba D. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of alpha-adrenergic and imidazoline receptor ligands. J Pharm Pharm Sci. 2013;16(4):622\u201347.","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"821_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.neuroscience.2007.01.031","volume":"146","author":"P Szot","year":"2007","unstructured":"Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007;146(1):471\u201380.","journal-title":"Neuroscience"},{"key":"821_CR40","doi-asserted-by":"crossref","unstructured":"Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018;27(3):340\u20138. This is the first report linking tamsulosin to the risk of developing dementia. The authors outline a plausible mechanism of action and provide support from Medicare claims data","DOI":"10.1002\/pds.4361"},{"issue":"3","key":"821_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","volume":"12","author":"ER Mayeda","year":"2016","unstructured":"Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12(3):216\u201324.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"821_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1212\/WNL.51.3.728","volume":"51","author":"AF Jorm","year":"1998","unstructured":"Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51(3):728\u201333.","journal-title":"Neurology"},{"issue":"3","key":"821_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/pds.4382","volume":"27","author":"SS Gill","year":"2018","unstructured":"Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018;27(3):349\u201350. This editorial comment accompanied reference #40. The authors support the idea of a causal link between tamsulosin and dementia and encourage future trials to prove this relationship","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-018-0821-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T14:25:36Z","timestamp":1751725536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-018-0821-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s11934-018-0821-0","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"type":"print","value":"1527-2737"},{"type":"electronic","value":"1534-6285"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"3 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jason K. Frankel, Yinghui Duan, and Peter C. Albertsen each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"69"}}